Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma-Reference-Cited by-同舟云学术

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Published:2021-11-11 Issue: Volume: Page:
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Grossmann Kenneth F.^ORCID,Othus Megan,Patel Sapna P.^ORCID,Tarhini Ahmad A.^ORCID,Sondak Vernon K.^ORCID,Knopp Michael V.,Petrella Teresa M.,Truong Thach-Giao,Khushalani Nikhil I.,Cohen Justine V.,Buchbinder Elizabeth I.,Kendra Kari^ORCID,Funchain Pauline^ORCID,Lewis Karl D.,Conry Robert M.,Chmielowski Bartosz^ORCID,Kudchadkar Ragini R.,Johnson Douglas B.,Li Hongli,Moon James,Eroglu Zeynep,Gastman Brian,Kovacsovics-Bankowski Magdalena,Gunturu Krishna S.,Ebbinghaus Scot W.,Ahsan Sama,Ibrahim Nageatte^ORCID,Sharon Elad^ORCID,Korde Larissa A.,Kirkwood John M.^ORCID,Ribas Antoni^ORCID

Funder

HHS | NIH | National Cancer Institute

Merck & Co., Inc. | Merck Sharp and Dohme

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Outcomes of adjuvant immune checkpoint inhibitor therapy in melanoma: a retrospective study;Acta Clinica Belgica;2024-09-13

3. Adjuvant PD-1-based therapies for high-risk resected melanomas are here to stay;The American Journal of Surgery;2024-09

4. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial;European Journal of Cancer;2024-09

5. Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment;Biomedicines;2024-08-08